Francis Burrows, Ph.D.: key facts
- Kind of voice
- Sector leader
- Role
- Chief Scientific Officer of Kura Oncology
- Quoted on
- Diabetes
- Press citations held
- 1
- Most recently quoted
- 29 Sept 2026
“Our preclinical findings have strengthened our conviction that menin inhibition has the potential to address the underlying loss of functional β-cell capacity, rather than simply managing its consequences. The consistency of the findings across Type 1 and Type 2 diabetes models, together with their translation into human islet systems, provides a strong rationale to advance KO-7246 into clinical development.”
Where Francis Burrows, Ph.D. has been quoted
- Kura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapyfiercebiotech.com · 29 Sept 2026
Chief executives, directors and spokespeople of trade bodies, representative associations and charities speaking for the sector. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 29 Sept 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.